# Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment

> **NCT07122024** · PHASE4 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 414 (estimated)

## Conditions studied

- Helicobacter Pylori

## Interventions

- **DRUG:** Keverprazan 10 days
- **DRUG:** Keverprazan 14 days
- **DRUG:** Rabeprazole

## Key facts

- **NCT ID:** NCT07122024
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-19
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-12-30
- **Target enrollment:** 414 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07122024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07122024, "Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07122024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*